Skip to content
Peptigraph home

SLU-PP-332

ERR agonist (not a peptide). SLU-PP-332 is not FDA approved for any use.

Also called:sluppSLU-PP
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Animal evidence, 2 of 4
StatusNot FDA approved · research chemicalWADA status unclearFull legal history

Key facts

Class
ERR agonist (not a peptide)
Not a peptide
Also called
slupp, SLU-PP
Vial sizes sold
5 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)
FDA status
Not approved
research chemical
WADA
Unclear
Not named on the 2026 list
Everything on SLU-PP-332

SLU-PP-332 guides

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

SLU-PP-332: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight lossNot in our ledgerNot in our ledger1Animal evidence, 2 of 4The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806
EnergyNot in our ledgerNot in our ledger3Animal evidence, 2 of 4The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Not a peptide: a synthetic ERR agonist called an exercise mimetic

SLU-PP-332 is a small synthetic agonist of the estrogen-related receptors (ERR alpha, beta and gamma), so it is not a peptide.[7]

In mice it increased oxidative skeletal-muscle fibres and enhanced exercise endurance. This is mouse data.[8]

Everything is preclinical

In models of metabolic syndrome, the ERR agonist reduced obesity and improved insulin sensitivity.[3]

In a mouse pressure-overload heart-failure model, SLU-PP-332 and an analogue improved ejection fraction, reduced fibrosis and increased survival.[9]

A systematic review of ERR activation as an exercise mimetic concludes that clinical trials are needed to confirm efficacy and safety in humans.[10]

The one human-tissue study treated muscle cells grown in culture from biopsies of inactive women, not people.[11]

Regulatory path and sport

Drugs@FDA has no SLU-PP-332 product.[2]

A doping-control paper on its metabolites states that WADA prohibits exercise mimetics and metabolic modulators; the compound is not named on the list itself.[7]

Compared with

Common stacks

SLU-PP-332 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Common questions

Is SLU-PP-332 FDA approved?

No. SLU-PP-332 is not FDA approved for any use.

Is SLU-PP-332 a peptide?

No. It is a err agonist. It is listed here because people research it alongside peptides.

How much water goes in a 5 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 2.5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is SLU-PP-332?

A small synthetic ERR agonist, not a peptide.[7]

What does SLU-PP-332 do?

In mouse models of metabolic syndrome it reduced obesity and improved insulin sensitivity. No human trial was found.[3]

Is there an oral SLU-PP-332?

No human trial of SLU-PP-332 was found in any form; a systematic review of ERR activation as an exercise mimetic concludes that clinical trials are needed.[10]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "SLU-PP-332" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
  4. 4PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  7. 7Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
  8. 8Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
  9. 9Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Circulation · 2024PMID 37961903Accessed 2 Oct 2026
  10. 10[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
  11. 11Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026

Found an error? Report a correction.